| Field | Row 1 |
|---|---|
| adsh | 0001558370-25-007036 |
| cik | 1604821 |
| name | NATERA, INC. |
| sic | 8071 |
| countryba | US |
| stprba | TX |
| cityba | AUSTIN |
| zipba | 78753 |
| bas1 | 13011 MCCALLEN PASS |
| bas2 | BUILDING A SUITE 100 |
| baph | 650-249-9090 |
| countryma | US |
| stprma | TX |
| cityma | AUSTIN |
| zipma | 78753 |
| mas1 | 13011 MCCALLEN PASS |
| mas2 | BUILDING A SUITE 100 |
| countryinc | US |
| stprinc | DE |
| ein | 010894487 |
| former | |
| changed | |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250509 |
| accepted | 2025-05-08 19:36:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | ntra-20250331x10q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-007036 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | 24071000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Accounts Payable Current | 34922000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20231231 | Common Stock Shares Issued | 119581000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20250331 | Contract With Customer Liability Current | 1500000.0000 | USD | 0 | us-gaap/2023 | Counterparty Name= Foundation Medicine Inc.; | ||
| 0001558370-25-007036 | 20240331 | Cost Of Goods And Services Sold | 158833000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Single Reportable Segment; Product Or Service= Product; | ||
| 0001558370-25-007036 | 20240331 | Cost Of Goods And Services Sold | 158833000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Product; | ||
| 0001558370-25-007036 | 20250331 | Earnings Per Share Basic | -0.5000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Earnings Per Share Diluted | -0.5600 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Employee Related Liabilities Current | 62114000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Accounts Payable | 2379000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Interest Expense | 3124000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Interest Income Expense Nonoperating Net | 13419000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Interest Paid Net | 1005000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Inventory Net | 50367000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Liabilities And Stockholders Equity | 1660735000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Net Cash Provided By Used In Financing Activities | 544000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Non Cash Interest Expense | -1000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20250331 | Other Assets Noncurrent | 40897000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Profit Loss | -66936000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Retained Earnings Accumulated Deficit | -2567862000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 5178000.0000 | USD | 1 | us-gaap/2023 | Geographical= E M E A; | ||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 341028000.0000 | USD | 1 | us-gaap/2023 | Major Customers= Insurance Carriers; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 20832000.0000 | USD | 1 | us-gaap/2023 | Major Customers= Laboratory Partners; | ||
| 0001558370-25-007036 | 20240331 | Share Based Compensation | 64447000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Short Term Borrowings | 80362000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20231231 | Stockholders Equity | -2377436000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007036 | 20241231 | Stockholders Equity | 1195420000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Stockholders Equity | -2567862000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 2000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 544000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 134750000.0000 | shares | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Accounts Receivable Net Current | 314165000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20231231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -3085000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -197000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | 24071000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20250331 | Allowance For Doubtful Accounts Receivable Current | 7434000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Assets Current | 1375820000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 813817000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Common Stock Shares Issued | 135932000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Cost Of Goods And Services Sold | 307000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Licensing And Other; | ||
| 0001558370-25-007036 | 20240331 | Depreciation Depletion And Amortization | 7063000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Employee Related Liabilities | 17035000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Operating Lease Liability | -4122000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 9354000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Interest Expense | 1000000.0000 | USD | 1 | us-gaap/2023 | Debt Instrument= Line Of Credit Ubs; | ||
| 0001558370-25-007036 | 20241231 | Liabilities | 465315000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Liabilities | 492691000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Liabilities Current | 344045000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Net Cash Provided By Used In Operating Activities | 27001000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Net Income Loss | -67599000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Operating Lease Cost | 3593000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Operating Lease Right Of Use Asset | 86149000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Other Liabilities Current | 146893000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Premium Amortization And Discount Accretion On Investment Securities | 9000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20240331 | Proceeds From Stock Options Exercised | 6466000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Profit Loss | -67599000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 6049000.0000 | USD | 1 | us-gaap/2023 | Geographical= E M E A; | ||
| 0001558370-25-007036 | 20240331 | Stockholders Equity | 794111000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Stockholders Equity | -2192000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007036 | 20240331 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20241231 | Stockholders Equity | 12000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20250331 | Stockholders Equity | 14000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Shares Bonus | 222000.0000 | shares | 1 | 0001558370-25-007036 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 792000.0000 | shares | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 1000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 2000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 544000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20240331 | Amortization Of Debt Discount Premium | 328000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -344000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 112000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 4223000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 642095000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2023 | ||||
| 0001558370-25-007036 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Contract With Customer Liability Current | 18600000.0000 | USD | 0 | us-gaap/2023 | Product Or Service= Genetic Testing Services; | ||
| 0001558370-25-007036 | 20250331 | Cost Of Goods And Services Sold | 184613000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Single Reportable Segment; Product Or Service= Product; | ||
| 0001558370-25-007036 | 20250331 | Employee Related Liabilities Current | 47086000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Fair Value Adjustment Of Warrants | -3235000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Inventories | 5623000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -14428000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Interest Paid Net | 1179000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Liabilities Current | 365677000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Marketable Securities Current | 22689000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Operating Income Loss | -74314000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Operating Lease Liability Noncurrent | 96588000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Operating Lease Right Of Use Asset | 94631000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Proceeds From Stock Options Exercised | 544000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 367741000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1669000.0000 | USD | 1 | us-gaap/2023 | Geographical= Other Geographic Areas; | ||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 20276000.0000 | USD | 1 | us-gaap/2023 | Major Customers= Laboratory Partners; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1692000.0000 | USD | 1 | us-gaap/2023 | Geographical= Americas Excluding Us; | ||
| 0001558370-25-007036 | 20250331 | Selling General And Administrative Expense | 266864000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Share Based Compensation | 77827000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20231231 | Stockholders Equity | 765327000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 1591000.0000 | shares | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 6466000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 120814000.0000 | shares | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Accounts Receivable Net Current | 318233000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 64952000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 64952000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20241231 | Allowance For Doubtful Accounts Receivable Current | 7259000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Assets | 1732366000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20200430 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2023 | Longterm Debt Type= Convertible Notes Payable; | ||
| 0001558370-25-007036 | 20241231 | Common Stock Shares Authorized | 750000000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Common Stock Shares Issued | 132646000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Comprehensive Income Net Of Tax | -66706000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Contract With Customer And Other Liabilities Noncurrent | 24682000.0000 | USD | 0 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20250331 | Contract With Customer Liability Current | 20557000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Cost Of Goods And Services Sold | 452000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Licensing And Other; | ||
| 0001558370-25-007036 | 20250331 | Costs And Expenses | 581007000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Employee Related Liabilities | 17789000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Other Accrued Liabilities | 26866000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Interest Income Expense Nonoperating Net | 10267000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Net Cash Provided By Used In Financing Activities | 6466000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Net Cash Provided By Used In Investing Activities | 138255000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Net Income Loss | -66936000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007036 | 20241231 | Other Assets Noncurrent | 36720000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | 893000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Research And Development Expense | 88637000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Retained Earnings Accumulated Deficit | -2634798000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 3069000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Licensing And Other; | ||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 364672000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Product; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 472647000.0000 | USD | 1 | us-gaap/2023 | Major Customers= Insurance Carriers; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1794000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Licensing And Other; | ||
| 0001558370-25-007036 | 20250331 | Short Term Borrowings | 80345000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Shares Bonus | 270000.0000 | shares | 1 | 0001558370-25-007036 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 6466000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 134750000.0000 | shares | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | 32063000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 973768000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 171722000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 28181000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Common Stock Shares Issued | 122234000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20250331 | Depreciation Depletion And Amortization | 9237000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Earnings Per Share Diluted | -0.5000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -67171000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Income Tax Expense Benefit | 428000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Accounts Receivable | 10459000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Interest Expense | 1200000.0000 | USD | 1 | us-gaap/2023 | Debt Instrument= Line Of Credit Ubs; | ||
| 0001558370-25-007036 | 20250331 | Net Cash Provided By Used In Investing Activities | -16815000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Noncash Expense Recovery | 361000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | 147000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax | 147000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007036 | 20250331 | Other Liabilities Current | 178449000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Premium Amortization And Discount Accretion On Investment Securities | -460000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 8351000.0000 | USD | 1 | us-gaap/2023 | Major Customers= Patients; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 500036000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Product; | ||
| 0001558370-25-007036 | 20240331 | Selling General And Administrative Expense | 194278000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Stock Based Compensation Included In Capitalized Software Development Costs | 608000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 120814000.0000 | shares | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Accounts Payable Current | 39240000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Additional Paid In Capital Common Stock | 3874656000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Assets | 1660735000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 945587000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Contract With Customer And Other Liabilities Noncurrent | 23958000.0000 | USD | 0 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20240331 | Costs And Expenses | 442055000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Income Tax Expense Benefit | 173000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Contract With Customer Liability | 793000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Inventories | 2265000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Net Income Loss | -67599000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007036 | 20240331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -2192000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | 32063000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 78435000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 78435000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2023 | ||||
| 0001558370-25-007036 | 20250331 | Common Stock Shares Authorized | 750000000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Common Stock Shares Issued | 132646000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Common Stock Shares Outstanding | 132646000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Common Stock Value | 14000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Contract With Customer Liability Current | 19754000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Cost Of Goods And Services Sold | 307000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Single Reportable Segment; Product Or Service= Licensing And Other; | ||
| 0001558370-25-007036 | 20250331 | Cost Of Goods And Services Sold | 452000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Single Reportable Segment; Product Or Service= Licensing And Other; | ||
| 0001558370-25-007036 | 20250331 | Cost Of Goods And Services Sold | 184613000.0000 | USD | 1 | us-gaap/2023 | Product Or Service= Product; | ||
| 0001558370-25-007036 | 20250331 | Foreign Currency Transaction Gain Loss Before Tax | -138000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Accounts Payable | 10732000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Interest Expense | 1005000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Inventory Net | 44744000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Liabilities And Stockholders Equity | 1732366000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Marketable Securities Current | 17832000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Operating Lease Liability Noncurrent | 103056000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax | 893000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Payments To Acquire Assets | 10495000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20240331 | Payments To Acquire Property Plant And Equipment | 20315000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Prepaid Expense And Other Assets Current | 48635000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 5000000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 359413000.0000 | USD | 1 | us-gaap/2023 | Geographical= U S; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1784000.0000 | USD | 1 | us-gaap/2023 | Geographical= Other Geographic Areas; | ||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 492305000.0000 | USD | 1 | us-gaap/2023 | Geographical= U S; | ||
| 0001558370-25-007036 | 20231231 | Stockholders Equity | -3085000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007036 | 20231231 | Stockholders Equity | 11000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Stockholders Equity | -2445035000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007036 | 20240331 | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 169065000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 367741000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1481000.0000 | USD | 1 | us-gaap/2023 | Geographical= Americas Excluding Us; | ||
| 0001558370-25-007036 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 6437000.0000 | USD | 1 | us-gaap/2023 | Major Customers= Patients; | ||
| 0001558370-25-007036 | 20240331 | Stock Based Compensation Included In Capitalized Software Development Costs | 505000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20240331 | Stockholders Equity | 3241326000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20241231 | Stockholders Equity | -344000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007036 | 20250331 | Stockholders Equity | 1239675000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Stockholders Equity | -197000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 50000.0000 | shares | 1 | us-gaap/2023 | Award Type= Employee And Non Employee Options; | ||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 50000.0000 | shares | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20241231 | Property Plant And Equipment Net | 162046000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Acquisition Of Warrants | 1884000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20241231 | Additional Paid In Capital Common Stock | 3763614000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Assets Current | 1416385000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Common Stock Shares Issued | 135932000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Common Stock Shares Outstanding | 135932000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20241231 | Common Stock Value | 12000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Comprehensive Income Net Of Tax | -66789000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Contract With Customer Liability Current | 500000.0000 | USD | 0 | us-gaap/2023 | Counterparty Name= Bgi Genomics Co Ltd; | ||
| 0001558370-25-007036 | 20240331 | Earnings Per Share Basic | -0.5600 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Foreign Currency Transaction Gain Loss Before Tax | -359000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -66763000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Accounts Receivable | 4068000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Contract With Customer Liability | 671000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Increase Decrease In Operating Lease Liability | -4505000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Increase Decrease In Other Accrued Liabilities | -7625000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Net Cash Provided By Used In Operating Activities | 44452000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Net Income Loss | -66936000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Non Cash Interest Expense | -17000.0000 | USD | 1 | 0001558370-25-007036 | |||
| 0001558370-25-007036 | 20250331 | Operating Income Loss | -79177000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Operating Lease Cost | 4389000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax | 893000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007036 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax | 147000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Payments To Acquire Property Plant And Equipment | 21815000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Prepaid Expense And Other Assets Current | 56185000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Property Plant And Equipment Net | 180453000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Research And Development Expense | 129078000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 501830000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-007036 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 501830000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007036 | 20231231 | Stockholders Equity | 3145837000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20241231 | Stockholders Equity | 3763614000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20250331 | Stockholders Equity | 3874656000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007036 | 20250331 | Stockholders Equity | -2634798000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007036 | 20250331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 3014000.0000 | shares | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-007036 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 1000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Common Stock; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Allowance For Doubtful Accounts Receivable Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Accounts Receivable, Allowance for Credit Loss, Current | Amount of allowance for credit loss on accounts receivable, classified as current. |
| Operating Lease Liability Noncurrent | us-gaap/2023 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2023 | 0 | 0 | monetary | I | C | Accumulated other comprehensive income | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Cost Of Goods And Services Sold | us-gaap/2023 | 0 | 0 | monetary | D | D | Cost of Goods and Services Sold | The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2023 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Interest Paid Net | us-gaap/2023 | 0 | 0 | monetary | D | C | Cash paid for interest | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Operating Income Loss | us-gaap/2023 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Assets Noncurrent | us-gaap/2023 | 0 | 0 | monetary | I | D | Other assets | Amount of noncurrent assets classified as other. |
| Additional Paid In Capital Common Stock | us-gaap/2023 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Common Stock Value | us-gaap/2023 | 0 | 0 | monetary | I | C | Common stock, $0.001 par value; 100,000,000 and 50,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 15,193,587 and 13,466,603 shares issued as of December 31, 2022 and December 31, 2021, respectively; 15,166,596 and 13,439,612 shares outstanding as of December 31, 2022 and December 31, 2021, respectively | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Non Cash Interest Expense | 0001558370-25-007036 | 1 | 0 | monetary | D | D | Non Cash Interest Expense | Amount of non-cash interest expense. |
| Premium Amortization And Discount Accretion On Investment Securities | 0001558370-25-007036 | 1 | 0 | monetary | D | D | Premium Amortization And Discount Accretion On Investment Securities | Amount of premium amortization and discount accretion on investment securities. |
| Earnings Per Share Basic | us-gaap/2023 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Interest Expense | us-gaap/2023 | 0 | 0 | monetary | D | D | Interest Expense | Amount of the cost of borrowed funds accounted for as interest expense. |
| Increase Decrease In Accounts Receivable | us-gaap/2023 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Marketable Securities Current | us-gaap/2023 | 0 | 0 | monetary | I | D | Marketable Securities, Current | Amount of investment in marketable security, classified as current. |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Proceeds From Stock Options Exercised | us-gaap/2023 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2023 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Stock Based Compensation Included In Capitalized Software Development Costs | 0001558370-25-007036 | 1 | 0 | monetary | D | D | Stock Based Compensation Included In Capitalized Software Development Costs | Amount of stock-based compensation included in capitalized software development costs. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2023 | 0 | 0 | monetary | D | C | Share-based expense | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Common Stock Shares Issued | us-gaap/2023 | 0 | 0 | shares | I | Common stock, shares issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Income Tax Expense Benefit | us-gaap/2023 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Liabilities And Stockholders Equity | us-gaap/2023 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2023 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Research And Development Expense | us-gaap/2023 | 0 | 0 | monetary | D | D | Research and development expenses | The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2023 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Profit Loss | us-gaap/2023 | 0 | 0 | monetary | D | C | Net Loss January 31,2023 | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2023 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Increase Decrease In Inventories | us-gaap/2023 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2023 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. |
| Net Income Loss | us-gaap/2023 | 0 | 0 | monetary | D | C | Net loss | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Assets Current | us-gaap/2023 | 0 | 0 | monetary | I | D | Assets, Current | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. |
| Common Stock Shares Outstanding | us-gaap/2023 | 0 | 0 | shares | I | Common stock, shares outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Earnings Per Share Diluted | us-gaap/2023 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Net Cash Provided By Used In Operating Activities | us-gaap/2023 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | Gain (Loss), Foreign Currency Transaction, before Tax | Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. |
| Operating Lease Right Of Use Asset | us-gaap/2023 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax | Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Selling General And Administrative Expense | us-gaap/2023 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Short Term Borrowings | us-gaap/2023 | 0 | 0 | monetary | I | C | Short-Term Debt | Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. |
| Property Plant And Equipment Net | us-gaap/2023 | 0 | 0 | monetary | I | D | Property and equipment, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Increase Decrease In Accounts Payable | us-gaap/2023 | 0 | 0 | monetary | D | D | Increase/(decrease) in accounts payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Fair Value Adjustment Of Warrants | us-gaap/2023 | 0 | 0 | monetary | D | D | Fair Value Adjustment of Warrants | Amount of expense (income) related to adjustment to fair value of warrant liability. |
| Increase Decrease In Contract With Customer Liability | us-gaap/2023 | 0 | 0 | monetary | D | D | Increase (Decrease) in Contract with Customer, Liability | Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. |
| Contract With Customer And Other Liabilities Noncurrent | 0001558370-25-007036 | 1 | 0 | monetary | I | C | Contract With Customer And Other Liabilities Noncurrent | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, and other liabilities classified as noncurrent. |
| Amortization Of Debt Discount Premium | us-gaap/2023 | 0 | 0 | monetary | D | D | Amortization of Debt Discount (Premium) | Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. |
| Assets | us-gaap/2023 | 0 | 0 | monetary | I | D | Assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. |
| Common Stock Shares Authorized | us-gaap/2023 | 0 | 0 | shares | I | Common stock, shares authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Retained Earnings Accumulated Deficit | us-gaap/2023 | 0 | 0 | monetary | I | C | Accumulated deficit | Amount of accumulated undistributed earnings (deficit). |
| Other Liabilities Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2023 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | us-gaap/2023 | 0 | 0 | monetary | D | D | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale | Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Commitments And Contingencies | us-gaap/2023 | 0 | 0 | monetary | I | C | Commitments and contingencies (Note 14) | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Prepaid Expense And Other Assets Current | us-gaap/2023 | 0 | 0 | monetary | I | D | Prepaid expenses and other | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2023 | 0 | 0 | shares | D | Options exercised | Number of share options (or share units) exercised during the current period. | |
| Depreciation Depletion And Amortization | us-gaap/2023 | 0 | 0 | monetary | D | D | Depreciation expense | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Contract With Customer Liability Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Current | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. |
| Costs And Expenses | us-gaap/2023 | 0 | 0 | monetary | D | D | Costs and Expenses | Total costs of sales and operating expenses for the period. |
| Increase Decrease In Employee Related Liabilities | us-gaap/2023 | 0 | 0 | monetary | D | D | Increase (Decrease) in Employee Related Liabilities | The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2023 | 0 | 0 | perShare | I | Common stock, par value | Face amount or stated value per share of common stock. | |
| Employee Related Liabilities Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Accrued payroll and benefits | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Liabilities | us-gaap/2023 | 0 | 0 | monetary | I | C | Liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | us-gaap/2023 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other. |
| Inventory Net | us-gaap/2023 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Noncash Expense Recovery | 0001558370-25-007036 | 1 | 0 | monetary | D | C | Noncash Expense Recovery | Amount of noncash expense recovery. |
| Stock Issued During Period Shares Bonus | 0001558370-25-007036 | 1 | 0 | shares | D | Stock Issued During Period Shares Bonus | Number of shares of stock issued attributable to bonus. | |
| Share Based Compensation | us-gaap/2023 | 0 | 0 | monetary | D | D | Share-based compensation | Amount of noncash expense for share-based payment arrangement. |
| Payments To Acquire Assets | 0001558370-25-007036 | 1 | 0 | monetary | D | C | Payments To Acquire Assets | Amount of cash outflow due to acquisition of assets. |
| Increase Decrease In Operating Lease Liability | us-gaap/2023 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Interest Income Expense Nonoperating Net | us-gaap/2023 | 0 | 0 | monetary | D | C | Interest Income (Expense), Nonoperating, Net | The net amount of nonoperating interest income (expense). |
| Acquisition Of Warrants | 0001558370-25-007036 | 1 | 0 | monetary | D | D | Acquisition Of Warrants | Amount of warrants acquired. |
| Accounts Payable Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Accounts payable | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2023 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Liabilities Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2023 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Stockholders Equity | us-gaap/2023 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2023 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accounts Receivable Net Current | us-gaap/2023 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Comprehensive Income Net Of Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Increase Decrease In Other Accrued Liabilities | us-gaap/2023 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Accrued Liabilities | The increase (decrease) during the reporting period in other expenses incurred but not yet paid. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2023 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Operating Lease Cost | us-gaap/2023 | 0 | 0 | monetary | D | D | Operating Lease, Cost | Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. |
| Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2023 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-007036 | 2 | 3 | BS | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | Cash, cash equivalents and restricted cash | 0 |
| 0001558370-25-007036 | 2 | 4 | BS | 0 | H | Marketable Securities Current | us-gaap/2023 | Short-term investments | 0 |
| 0001558370-25-007036 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2023 | Accounts receivable, net of allowance of $7,434 and $7,259 at March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001558370-25-007036 | 2 | 6 | BS | 0 | H | Inventory Net | us-gaap/2023 | Inventory | 0 |
| 0001558370-25-007036 | 2 | 7 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2023 | Prepaid expenses and other current assets, net | 0 |
| 0001558370-25-007036 | 2 | 8 | BS | 0 | H | Assets Current | us-gaap/2023 | Total current assets | 0 |
| 0001558370-25-007036 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2023 | Property and equipment, net | 0 |
| 0001558370-25-007036 | 2 | 10 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2023 | Operating lease right-of-use assets | 0 |
| 0001558370-25-007036 | 2 | 11 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2023 | Other assets | 0 |
| 0001558370-25-007036 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2023 | Total assets | 0 |
| 0001558370-25-007036 | 2 | 15 | BS | 0 | H | Accounts Payable Current | us-gaap/2023 | Accounts payable | 0 |
| 0001558370-25-007036 | 2 | 16 | BS | 0 | H | Employee Related Liabilities Current | us-gaap/2023 | Accrued compensation | 0 |
| 0001558370-25-007036 | 2 | 17 | BS | 0 | H | Other Liabilities Current | us-gaap/2023 | Other accrued liabilities | 0 |
| 0001558370-25-007036 | 2 | 18 | BS | 0 | H | Contract With Customer Liability Current | us-gaap/2023 | Deferred revenue, current portion | 0 |
| 0001558370-25-007036 | 2 | 19 | BS | 0 | H | Short Term Borrowings | us-gaap/2023 | Short-term debt financing | 0 |
| 0001558370-25-007036 | 2 | 20 | BS | 0 | H | Liabilities Current | us-gaap/2023 | Total current liabilities | 0 |
| 0001558370-25-007036 | 2 | 21 | BS | 0 | H | Contract With Customer And Other Liabilities Noncurrent | 0001558370-25-007036 | Deferred revenue, long-term portion and other liabilities | 0 |
| 0001558370-25-007036 | 2 | 22 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2023 | Operating lease liabilities, long-term portion | 0 |
| 0001558370-25-007036 | 2 | 23 | BS | 0 | H | Liabilities | us-gaap/2023 | Total liabilities | 0 |
| 0001558370-25-007036 | 2 | 24 | BS | 0 | H | Commitments And Contingencies | us-gaap/2023 | Commitments and contingencies (Note 8) | 0 |
| 0001558370-25-007036 | 2 | 26 | BS | 0 | H | Common Stock Value | us-gaap/2023 | Common stock, $0.0001 par value: 750,000 shares authorized at both March 31, 2025 and December 31, 2024; 135,932 and 132,646 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001558370-25-007036 | 2 | 27 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2023 | Additional paid-in capital | 0 |
| 0001558370-25-007036 | 2 | 28 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2023 | Accumulated deficit | 0 |
| 0001558370-25-007036 | 2 | 29 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2023 | Accumulated other comprehensive loss | 0 |
| 0001558370-25-007036 | 2 | 30 | BS | 0 | H | Stockholders Equity | us-gaap/2023 | Total stockholders' equity | 0 |
| 0001558370-25-007036 | 2 | 31 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2023 | Total liabilities and stockholders' equity | 0 |
| 0001558370-25-007036 | 3 | 1 | BS | 1 | H | Allowance For Doubtful Accounts Receivable Current | us-gaap/2023 | Allowances on accounts receivable | 0 |
| 0001558370-25-007036 | 3 | 2 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2023 | Common stock, par value (in dollars per share) | 0 |
| 0001558370-25-007036 | 3 | 3 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2023 | Common stock, shares authorized | 0 |
| 0001558370-25-007036 | 3 | 4 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2023 | Common stock, shares issued | 0 |
| 0001558370-25-007036 | 3 | 5 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2023 | Common stock, shares outstanding | 0 |
| 0001558370-25-007036 | 4 | 8 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2023 | Total revenues | 0 |
| 0001558370-25-007036 | 4 | 10 | IS | 0 | H | Cost Of Goods And Services Sold | us-gaap/2023 | Cost of revenues | 0 |
| 0001558370-25-007036 | 4 | 11 | IS | 0 | H | Research And Development Expense | us-gaap/2023 | Research and development | 0 |
| 0001558370-25-007036 | 4 | 12 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2023 | Selling, general and administrative | 0 |
| 0001558370-25-007036 | 4 | 13 | IS | 0 | H | Costs And Expenses | us-gaap/2023 | Total cost and expenses | 0 |
| 0001558370-25-007036 | 4 | 14 | IS | 0 | H | Operating Income Loss | us-gaap/2023 | Loss from operations | 0 |
| 0001558370-25-007036 | 4 | 15 | IS | 0 | H | Interest Expense | us-gaap/2023 | Interest expense | 1 |
| 0001558370-25-007036 | 4 | 16 | IS | 0 | H | Interest Income Expense Nonoperating Net | us-gaap/2023 | Interest and other income, net | 0 |
| 0001558370-25-007036 | 4 | 17 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2023 | Loss before income taxes | 0 |
| 0001558370-25-007036 | 4 | 18 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2023 | Income tax expense | 1 |
| 0001558370-25-007036 | 4 | 19 | IS | 0 | H | Net Income Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-007036 | 4 | 20 | IS | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2023 | Unrealized gain on available-for-sale securities, net of tax | 0 |
| 0001558370-25-007036 | 4 | 21 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2023 | Comprehensive loss | 0 |
| 0001558370-25-007036 | 4 | 23 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2023 | Basic (in dollars per share) | 0 |
| 0001558370-25-007036 | 4 | 24 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2023 | Diluted (in dollars per share) | 0 |
| 0001558370-25-007036 | 4 | 26 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2023 | Basic (in shares) | 0 |
| 0001558370-25-007036 | 4 | 27 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2023 | Diluted (in shares) | 0 |
| 0001558370-25-007036 | 5 | 9 | EQ | 0 | H | Stockholders Equity | us-gaap/2023 | Balance | 0 |
| 0001558370-25-007036 | 5 | 10 | EQ | 0 | H | Common Stock Shares Issued | us-gaap/2023 | Balance (in shares) | 0 |
| 0001558370-25-007036 | 5 | 11 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2023 | Issuance of common stock upon exercise of stock options | 0 |
| 0001558370-25-007036 | 5 | 12 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2023 | Issuance of common stock upon exercise of stock options (in shares) | 0 |
| 0001558370-25-007036 | 5 | 13 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | us-gaap/2023 | Issuance of common stock for bonus | 0 |
| 0001558370-25-007036 | 5 | 14 | EQ | 0 | H | Stock Issued During Period Shares Bonus | 0001558370-25-007036 | Issuance of common stock for bonus (in shares) | 0 |
| 0001558370-25-007036 | 5 | 15 | EQ | 0 | H | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2023 | Vesting of restricted stock units | 0 |
| 0001558370-25-007036 | 5 | 16 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2023 | Vesting of restricted stock units (in shares) | 0 |
| 0001558370-25-007036 | 5 | 17 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2023 | Stock based compensation | 0 |
| 0001558370-25-007036 | 5 | 18 | EQ | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax | us-gaap/2023 | Unrealized gain loss on available-for sale securities | 0 |
| 0001558370-25-007036 | 5 | 19 | EQ | 0 | H | Net Income Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-007036 | 5 | 20 | EQ | 0 | H | Stockholders Equity | us-gaap/2023 | Balance | 0 |
| 0001558370-25-007036 | 5 | 21 | EQ | 0 | H | Common Stock Shares Issued | us-gaap/2023 | Balance (in shares) | 0 |
| 0001558370-25-007036 | 6 | 2 | CF | 0 | H | Profit Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-007036 | 6 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2023 | Depreciation and amortization | 0 |
| 0001558370-25-007036 | 6 | 5 | CF | 0 | H | Premium Amortization And Discount Accretion On Investment Securities | 0001558370-25-007036 | Amortization of premiums and accretion of purchase discounts on investment securities | 0 |
| 0001558370-25-007036 | 6 | 6 | CF | 0 | H | Share Based Compensation | us-gaap/2023 | Stock-based compensation | 0 |
| 0001558370-25-007036 | 6 | 7 | CF | 0 | H | Operating Lease Cost | us-gaap/2023 | Non-cash lease expense | 0 |
| 0001558370-25-007036 | 6 | 8 | CF | 0 | H | Noncash Expense Recovery | 0001558370-25-007036 | Non-cash expense recovery | 1 |
| 0001558370-25-007036 | 6 | 9 | CF | 0 | H | Amortization Of Debt Discount Premium | us-gaap/2023 | Amortization of debt discount and issuance cost | 0 |
| 0001558370-25-007036 | 6 | 10 | CF | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2023 | Change in fair value of warrants and preferred stock | 0 |
| 0001558370-25-007036 | 6 | 11 | CF | 0 | H | Foreign Currency Transaction Gain Loss Before Tax | us-gaap/2023 | Foreign exchange adjustment | 1 |
| 0001558370-25-007036 | 6 | 12 | CF | 0 | H | Non Cash Interest Expense | 0001558370-25-007036 | Non-cash interest expense | 0 |
| 0001558370-25-007036 | 6 | 14 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2023 | Accounts receivable | 1 |
| 0001558370-25-007036 | 6 | 15 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2023 | Inventory | 1 |
| 0001558370-25-007036 | 6 | 16 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2023 | Prepaid expenses and other assets | 1 |
| 0001558370-25-007036 | 6 | 17 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2023 | Accounts payable | 0 |
| 0001558370-25-007036 | 6 | 18 | CF | 0 | H | Increase Decrease In Employee Related Liabilities | us-gaap/2023 | Accrued compensation | 0 |
| 0001558370-25-007036 | 6 | 19 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2023 | Operating lease liabilities | 0 |
| 0001558370-25-007036 | 6 | 20 | CF | 0 | H | Increase Decrease In Other Accrued Liabilities | us-gaap/2023 | Other accrued liabilities | 0 |
| 0001558370-25-007036 | 6 | 21 | CF | 0 | H | Increase Decrease In Contract With Customer Liability | us-gaap/2023 | Deferred revenue | 0 |
| 0001558370-25-007036 | 6 | 22 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2023 | Cash provided by operating activities | 0 |
| 0001558370-25-007036 | 6 | 24 | CF | 0 | H | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | us-gaap/2023 | Proceeds from maturity of investments | 0 |
| 0001558370-25-007036 | 6 | 25 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2023 | Purchases of property and equipment, net | 1 |
| 0001558370-25-007036 | 6 | 26 | CF | 0 | H | Payments To Acquire Assets | 0001558370-25-007036 | Cash paid for acquisition of intangible assets | 1 |
| 0001558370-25-007036 | 6 | 27 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2023 | Cash provided by (used in) investing activities | 0 |
| 0001558370-25-007036 | 6 | 29 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2023 | Proceeds from exercise of stock options | 0 |
| 0001558370-25-007036 | 6 | 30 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2023 | Cash provided by financing activities | 0 |
| 0001558370-25-007036 | 6 | 31 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2023 | Net change in cash, cash equivalents and restricted cash | 0 |
| 0001558370-25-007036 | 6 | 32 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | Cash, cash equivalents and restricted cash, beginning of period | 0 |
| 0001558370-25-007036 | 6 | 33 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | Cash, cash equivalents and restricted cash, end of period | 0 |
| 0001558370-25-007036 | 6 | 35 | CF | 0 | H | Interest Paid Net | us-gaap/2023 | Cash paid for interest | 0 |
| 0001558370-25-007036 | 6 | 37 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2023 | Purchases of property and equipment in accounts payable and accruals | 0 |
| 0001558370-25-007036 | 6 | 38 | CF | 0 | H | Acquisition Of Warrants | 0001558370-25-007036 | Acquisition of warrants | 0 |
| 0001558370-25-007036 | 6 | 39 | CF | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition | us-gaap/2023 | Issuance of common stock for bonuses | 0 |
| 0001558370-25-007036 | 6 | 40 | CF | 0 | H | Stock Based Compensation Included In Capitalized Software Development Costs | 0001558370-25-007036 | Stock-based compensation included in capitalized software development costs | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |